NEWS

IN THE NEWS

Proof of concept for the Genetically Engineered Microbial Medicines (GEMM) platform came in a recent first-in-human, Phase I trial.

The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.

Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.

Shkreli’s former company Vyera settles for $40M in antitrust case, but ‘pharma bro’ still faces his own trial fkansteiner Tue, 12/07/2021 – 16:35

Proof of concept for the Genetically Engineered Microbial Medicines (GEMM) platform came in a recent first-in-human, Phase I trial.

The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.